Higher Serum-Soluble α-Klotho Level Does Not Predict Longer Survival after Stroke

Table 2

Comparison of survivors and patients who died during the period of follow-up.

	Survivors ()	Death ()
Age (years)			<0.001
Sex (men/women)	59/69	40/49	0.87
Previous stroke or transient ischemic attack (/%)	24 (18.7)	18 (20.2)	0.79
Concomitant diseases
Hypertension ( (%))	109 (85.2)	77 (86.5)	0.78
Ischemic heart disease ( (%))	31 (24.2)	32 (36.0)	0.06
Atrial fibrillation ( (%))	31 (24.2)	35 (39.3)	<0.05
Obesity ( (%))	24 (18.8)	18 (20.2)	0.79
Diabetes ( (%))	42 (32.8)	37 (41.6)	0.19
Hypercholesterolemia ( (%))
Medications before stroke
Aspirin ( (%))	28 (45.7)	49 (55.7)	0.15
Statin therapy ( (%))	47 (36.7)	37 (41.6)	0.47
Antithrombotic agents ( (%))	15 (11.7)	12 (13.5)	0.70
Addictions
Active smokers ( (%))	31 (24.2)	14 (15.7)	0.13
Addicted to alcohol ( (%))	4 (3.1)	6 (6.7)	0.32
Type of stroke
Large vessel occlusion ( (%))	62 (48.4)	44 (49.4)	<0.05
Lacunar ( (%))	41 (32.1)	15 (16.9)
Embolic ( (%))	25 (19.5)	30 (33.7)
Stroke severity
NIHSS-I score			<0.001
Laboratory findings
Total cholesterol (mmol/L)			0.07
LDL cholesterol (mmol/L)			<0.05
HDL cholesterol (mmol/L)			0.44
Triglycerides (mmol/L)	1.59 (1.15–2.28)	1.23 (0.96–1.56)	<0.001
Creatinine (μmol/L)	78.9 (69.0–89.2)	84.4 (72.9–99.1)	0.08
Estimated glomerular filtration rate—eGFR (mL/min/1.73 m^2)			<0.05
CKD ( or albuminuria) ( (%))	41 (32.0)	39 (43.8)	0.08
C-reactive protein (mg/dL)	3.82 (1.60–9.21)	4.22 (2.09–9.36)	0.30
Calcium (mg/dL)	2.30 (2.18–2.45)	2.29 (2.20–2.45)	0.69
Phosphorus (mg/dL)	1.13 (0.98–1.38)	1.11 (0.93–1.32)	0.62
Intact parathyroid hormone (pg/mL)	37.3 (22.8–54.2)	42.6 (29.7–65.1)	0.08
Intact fibroblast growth factor 23—iFGF23 (pg/mL)	54.3 (17.6–86.2)	51.5 (25.3–84.9)	0.48
Soluble α-Klotho (pg/mL)	627.1 (386.6–870.2)	689.3 (470.8–983.6)	0.18
Klotho/iFGF23	11.5 (6.5–30.5)	14.4 (7.7–26.7)	0.89

or median (lower quartile-upper quartile).